机构：[1]Department of Oncology, The Afliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan, People’s Republic of China[2]Laboratory of Molecular Pharmacology, Southwest Medical University, Luzhou 646000, Sichuan, People’s Republic of China[3]Department of Pathophysiology, College of Basic Medical Science, Southwest Medical University, Luzhou 646000, Sichuan, People’s Republic of China[4]South Sichuan Institute of Translational Medicine, Luzhou 646000, Sichuan, People’s Republic of China.
Nanoparticles (NPs) have been increasingly studied for radiosensitization. The principle of NPs radio-enhancement is to use high-atomic number NPs (e.g. gold, hafnium, bismuth and gadolinium) or deliver radiosensitizing substances, such as cisplatin and selenium. Nowadays, cancer immunotherapy is emerged as a promising treatment and immune checkpoint regulation has a potential property to improve clinical outcomes in cancer immunotherapy. Furthermore, NPs have been served as an ideal platform for immunomodulator system delivery. Owing to enhanced permeability and retention (EPR) effect, modified-NPs increase the targeting and retention of antibodies in target cells. The purpose of this review is to highlight the latest progress of nanotechnology in radiotherapy (RT) and immunotherapy, as well as combining these three strategies in cancer treatment. Overall, nanomedicine as an effective strategy for RT can significantly enhance the outcome of immunotherapy response and might be beneficial for clinical transformation.
基金：
Union Project of Luzhou
City and the Southwest Medical University (Nos. 14JC0144, 2013LZLY-J40).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类|2 区工程技术
小类|2 区生物工程与应用微生物3 区纳米科技
最新[2023]版：
大类|1 区生物学
小类|1 区生物工程与应用微生物2 区纳米科技
第一作者：
第一作者机构：[1]Department of Oncology, The Afliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan, People’s Republic of China
通讯作者：
通讯机构：[2]Laboratory of Molecular Pharmacology, Southwest Medical University, Luzhou 646000, Sichuan, People’s Republic of China[3]Department of Pathophysiology, College of Basic Medical Science, Southwest Medical University, Luzhou 646000, Sichuan, People’s Republic of China[4]South Sichuan Institute of Translational Medicine, Luzhou 646000, Sichuan, People’s Republic of China.
推荐引用方式(GB/T 7714)：
Jin Jing,Zhao Qijie.Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges.[J].Journal of nanobiotechnology.2020,18(1):75.doi:10.1186/s12951-020-00629-y.
APA：
Jin Jing&Zhao Qijie.(2020).Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges..Journal of nanobiotechnology,18,(1)
MLA：
Jin Jing,et al."Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges.".Journal of nanobiotechnology 18..1(2020):75
生物学